DarioHealth Corp. announced a new contract to provide its cardiometabolic solution to an employer beginning in January 2024. The Employer, a national financial and business services company, selected Dario to improve the cardiometabolic health of its population with an integrated solution for diabetes, pre-diabetes, weight management and hypertension along with tailored support for employees taking a GLP-1, or anti-obesity, medications.

Dario combines intelligent technologies and expert human support to deliver highly personalized experiences using insights from ten years of consumer engagement and is proven, in prior studies, to provide sustainable improvements in clinical outcomes.